Rastislav Bahleda
0009-0001-8245-0544
2 papers found
Refreshing results…
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
Missing publications? Search for publications with a matching author name.